Development of doxorubicin resistant rat prostate cancer cell lines
Replogle-Schwab, T.S.; Schwab, E.D.; Pienta, K.J.
Anticancer Research 17(6d): 4535-4538
1997
ISSN/ISBN: 0250-7005 PMID: 9494564 Document Number: 471333
One possible mechanism of chemotherapeutic resistance in patients with metastatic prostate cancer is the overexpression of P-glycoprotein. Additional tumor models are necessary to study this phenomenon. Doxorubicin resistant rat prostate cancer cell lines were developed by increasing doxorubicin levels in cell culture. The MDR lines (AT3B-1, AT3B-2, MLLB-1, and MLLB-2) were more resistant to vinblastine compared to controls. When P-glycoprotein was blocked, the AT3 MDR lines demonstrated efflux activity. Injection of AT3 MDR lines into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. MDR rat prostate cancer cells were developed. AT3B-1 and AT3B-2 cell lines have drug efflux pump ability, whereas the MLLB-1 and MLLB-2 may not, suggesting alternative key mechanisms other than P-glycoprotein overexpression. These new cell lines are being used to study chemotherapy resistance in prostate cancer.